THERAPEUTICS I PIPELINE

LightOx continue to develop their LXD191 candidate, a light activated chemotherapeutic agent for early stage mouth cancers.

LightOx has shown positive pre-clinical results and are planning on conducting a Phase I safety trial of LXD191 with partners in the UK.

Pipeline

PIPELINE

Mouth Cancer testing data helps catalyse the development of other clinical targets

Therapeutic Areas

LightOx also looks to expand with further candidates in alternative therapeutic areas including Project APOLLO focused on anti-fibrotic phototherapy for the treatment of patients with scleroderma, working with scientists at Radboudumc in The Netherlands.

APOLLO

OUR SOLUTION

LXD191

LightOx are developing a new class of light activated chemotherapy for the treatment of oral cancer. We use photosensitising agents along with light to kill cancer cells.

LIGHTOX

About

Our technologies lie in the design and synthesis of new chemical entities.